|
A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (pINN Sotorasib) for the Treatment of Subjects with Previously Treated Locally Advanced Unresectable/Metastatic NSCLC with KRAS p.G12C Mutation
|
Ongoing
|
AMG 510 (Sotorasib)
|
3
|
20190436
|
King Fahad Specialist Hospital (Dammam)
|
|
A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer
|
Completed
|
Pertuzumab + Trastuzumab +Taxane
|
3
|
MO28047
|
KFSH & RC-R
|
|
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
|
Completed
|
BMN 110
|
3
|
MOR-005
|
KFSH & RC-R
|
|
A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1)
|
Completed
|
A4250-005
|
3
|
A4250-005
|
KFSH&RC-R
|
|
A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
|
Completed
|
Sorafenib
|
3
|
BAY43-9006/14295
|
KFSH & RC-R
|
|
A Compartive Multicenter Study of Neoadjuvant Docetaxel/Cisplatin Followed by Concurrent Cisplatin with Radiotherapy using Intensity-Modulated Radition Therapy (IMRT) with or without Bevacizumab for Locally Advanced Nasopharyngeal Cancer
|
Completed
|
Docetaxel/Cisplatin and Bevacizumab
|
3
|
Version 1.3 date 6 may 2012
|
KFMC
|
|
A 96-week, two-arm, randomized, single-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy (CONDOR)
|
Completed
|
Brolucizumab
|
3
|
CRTH258D2301
|
DESH
|
|
A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
|
Completed
|
paliperidone
|
3
|
R092670SCH3015
|
JPH
|
|
A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed'
|
Completed
|
Budesonide + Formoterol VS. Budesonide + Terbutaline
|
3
|
D589SC00003
|
AFH-DH
|
|
A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
|
Completed
|
Travoprost 0.004% / Timolol
|
3
|
C-12-008
|
KKESH
|
